close 73% van de retail rekeningen verliezen gelden met de handel in CFD`s bij deze aanbieder. Investeringen zijn risicovol en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect. 73% van de retail beleggers lijdt verlies bij het handelen in CFD`s met deze aanbieder. Het is belangrijk dat u goed begrijpt hoe CFD`s werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
ZoekenZoeken
Change languageNederlands
Dashboard

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

JNJ

230.64

+1.43%↑

ISRG

496

-1.52%↓

ABT

109.39

+0.15%↑

RDY

13.59

+1.42%↑

NEOG

10.23

+0.2%↑

Home・Aandelen Lijst・MiNK Therapeutics
Search

MiNK Therapeutics

Gesloten

11.42 -2.64

Buy

Prijsupdate 2 feb 2026, 20:59 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

11.09

Max

11.6

Belangrijke statistieken

By Trading Economics

Inkomsten

1.4M

-2.9M

EPS

-0.65

Werknemers

23

EBITDA

1.3M

-2.8M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+197.11% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-2.3M

60M

Vorige openingsprijs

14.06

Vorige sluitingsprijs

11.42

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

7.81 / 8.1 Steun & Weerstand

MiNK Therapeutics Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 feb 2026, 23:52 UTC

Acquisities, Fusies, Overnames

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

DJ

Lezen

2 feb 2026, 23:52 UTC

Acquisities, Fusies, Overnames

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

DJ

Lezen

2 feb 2026, 23:48 UTC

Marktinformatie

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

DJ

Lezen

2 feb 2026, 23:38 UTC

Marktinformatie

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

DJ

Lezen

2 feb 2026, 23:28 UTC

Marktinformatie

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

DJ

Lezen

2 feb 2026, 23:23 UTC

Winsten

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

DJ

Lezen

2 feb 2026, 22:57 UTC

Winsten

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

DJ

Lezen

2 feb 2026, 22:22 UTC

Acquisities, Fusies, Overnames

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

DJ

Lezen

2 feb 2026, 22:08 UTC

Marktinformatie

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

DJ

Lezen

2 feb 2026, 21:51 UTC

Winsten

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

DJ

Lezen

2 feb 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

DJ

Lezen

2 feb 2026, 21:49 UTC

Winsten

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

DJ

Lezen

2 feb 2026, 21:39 UTC

Winsten

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

DJ

Lezen

2 feb 2026, 21:36 UTC

Winsten

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

DJ

Lezen

2 feb 2026, 21:34 UTC

Winsten

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

DJ

Lezen

2 feb 2026, 21:28 UTC

Acquisities, Fusies, Overnames

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

DJ

Lezen

2 feb 2026, 21:23 UTC

Winsten

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

DJ

Lezen

2 feb 2026, 21:19 UTC

Winsten

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

DJ

Lezen

2 feb 2026, 21:17 UTC

Winsten

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

DJ

Lezen

2 feb 2026, 21:17 UTC

Winsten

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

DJ

Lezen

2 feb 2026, 21:10 UTC

Winsten

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

DJ

Lezen

2 feb 2026, 21:08 UTC

Winsten

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

DJ

Lezen

2 feb 2026, 21:07 UTC

Winsten

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

DJ

Lezen

2 feb 2026, 21:05 UTC

Winsten

Palantir Technologies 4Q Net $608.7M >PLTR

DJ

Lezen

2 feb 2026, 21:05 UTC

Winsten

Palantir Technologies 4Q Rev $1.41B >PLTR

DJ

Lezen

2 feb 2026, 21:05 UTC

Winsten

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

DJ

Lezen

2 feb 2026, 21:05 UTC

Winsten

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

DJ

Lezen

2 feb 2026, 21:05 UTC

Winsten

Palantir Technologies 4Q Adj EPS 25c >PLTR

DJ

Lezen

2 feb 2026, 21:05 UTC

Winsten

Palantir Technologies 4Q EPS 24c >PLTR

DJ

Lezen

2 feb 2026, 20:40 UTC

Marktinformatie

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

DJ

Lezen

Peer Vergelijking

Prijswijziging

MiNK Therapeutics Prognose

Koersdoel

By TipRanks

197.11% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 35 USD  197.11%

Hoogste 35 USD

Laagste 35 USD

Gebaseerd op 1 Wall Street-analisten die 12-maands prijsdoelen bieden voor MiNK Therapeutics - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan MiNK Therapeutics - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

7.81 / 8.1Steun & Weerstand

Korte Termijn

Bullish Evidence

Recent bullish events outweigh bearish events.

Gemiddeld Termijn

Bullish Evidence

Recent bullish events outweigh bearish events.

Lange Termijn

Bearish Evidence

There is one bearish event.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Andere aandelen uit de sector

JNJ

Johnson and Johnson

230.64

↑ +1.43%

ISRG

Intuitive Surgical Inc

496

↓-1.52%

ABT

Abbott Laboratories

109.39

↑ +0.15%

RDY

Dr Reddy's Laboratories Ltd-ADR

13.59

↑ +1.42%

NEOG

Neogen Corp

10.23

↑ +0.2%
help-icon Live chat